Live Breaking News & Updates on ஹெப்ரான் நிறுவனம்|Page 2

Stay updated with breaking news from ஹெப்ரான் நிறுவனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene

Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.

France General , United States , Israel General , Comunidad Autonoma De Cataluna , Julien Mazie , Andreasn Saltos , Suddhasatta Acharyya , Hibiki Udagawa , Misako Nagasaka , Lyudmila Bazhenova , Luis Paz , Enriqueta Felip , Gustave Roussy , Yingkai Cheng , Egbertf Smit , Daiichi Sankyo , Javad Shahidi , Patrik Vitazka , David Planchard , Kazuhiko Nakagawa , Josem Pacheco , Ryota Shiga , Kapil Saxena , Bobt Li , Centre Hospitalier Universitaire , University Hospital ,

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial


May 06, 2021
published at 7:30 AMglobenewswire
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial
GlobeNewswire
May 06, 2021
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4
th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona.
Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid. ....

Israel General , Comunidad Autonoma De Cataluna , Manuela Niewel , Universitari Vall , Laura Soucek , Elena Garralda , Jimenez Diaz , Catalan Institute Of Research , Research Unit For Molecular Therapy Of Cancer , Hebron Institute Of Oncology , Early Clinical Drug Development Group , First Patient , Lead Compound , Hebron Institute , Catalan Institute , Advanced Studies , Hospital Universitari Vall , Hospital Universitario , Hospital Fundaci , Research Unit , Molecular Therapy , Principal Investigator , இஸ்ரேல் ஜநரல் , காமுனிடட தன்னாட்சி டி கடலுள் , ஜிமெனெஸ் டியாஸ் , கற்றலான் நிறுவனம் ஆஃப் ஆராய்ச்சி ,